Pancreatic Dermoid Cyst: A Rare Incidental Pancreatic Mass With Worrisome CT Features
A 5-cm Pancreatic Cystic Mass Discovered During CT Pulmonary Angiography
Executive Clinical Summary
A man in his 50s underwent CT pulmonary angiography (CTPA) because of exertional dyspnea and palpitations. Pulmonary embolism was not identified, but an unexpected cystic mass was detected in the pancreatic tail.
Dedicated pancreatic CT demonstrated an approximately 4.4 × 3.8 × 5.0 cm lobulated complex cystic lesion with an enhancing mural solid component. The main pancreatic duct was not clearly connected to the lesion. CA 19-9 was elevated to 90.0 kU/L, while CEA, AFP, and CA 15-3 were reported as normal.
These findings created a clinically important diagnostic problem. A large complex pancreatic cystic lesion with an enhancing solid component and elevated CA 19-9 cannot simply be labeled a benign incidental cyst. Branch-duct IPMN, cystic pancreatic neuroendocrine tumor, mucinous cystic neoplasm, and other cystic pancreatic lesions had to be considered.
The final diagnosis, however, was a pancreatic dermoid cyst—a very rare benign lesion.
The case illustrates a fundamental principle of radiology:
A lesion can have worrisome imaging features without ultimately being malignant, and the absence of a classic imaging feature does not necessarily exclude a rare diagnosis.
Key Clinical Questions
- What makes an incidental pancreatic cystic lesion clinically concerning?
- Why is an enhancing mural solid component more important than size alone?
- How does pancreatic duct communication help differentiate IPMN from other cystic lesions?
- Why can pancreatic dermoid cyst be difficult to diagnose before surgery?
- What are the complementary roles of CT, MRI/MRCP, EUS, and PET-CT?
- How could AI assist radiologists without replacing clinical judgment?
Introduction
Pancreatic cystic lesions are increasingly encountered as incidental findings on CT and MRI. The diagnostic challenge is not simply recognizing that a cyst exists. The real question is whether the lesion represents a low-risk benign process, a premalignant cystic neoplasm, or a lesion with malignant potential.
This distinction becomes particularly difficult when a lesion combines several apparently concerning characteristics.
The present case is a useful example. The pancreatic lesion was discovered incidentally during CTPA performed for symptoms unrelated to the pancreas. It was located in the pancreatic tail, measured approximately 5 cm, had a lobulated complex cystic morphology, and contained an enhancing mural solid component. CA 19-9 was also elevated.
These findings appropriately increased concern for a clinically significant pancreatic cystic neoplasm.
Yet the final pathology was a pancreatic dermoid cyst.
The diagnostic lesson is therefore broader than the diagnosis itself. Radiologists must recognize high-risk morphology, construct an appropriate differential diagnosis, and remain aware that rare benign entities can mimic more common neoplastic lesions.
Clinical Hook: The Pancreas Was Not the Reason for the Examination
The patient presented with exertional dyspnea and palpitations that had developed after a previous COVID-19 infection. His background history included type 2 diabetes mellitus, hypertension, dyslipidemia, and a relatively high BMI.
Laboratory evaluation showed a normal hemoglobin concentration, a low mean corpuscular volume of 70 fL, and an elevated D-dimer of 0.9 μg FEU/mL. CTPA was therefore performed to evaluate for pulmonary embolism.
No pulmonary embolism was identified.
Instead, the scan revealed an unexpected lesion in the pancreatic tail.
The patient did not report abdominal pain or digestive symptoms attributable to the pancreatic lesion.
This is a classic clinical setting for an incidental pancreatic cystic lesion: the pancreas becomes the focus of the diagnostic pathway even though the patient did not present because of pancreatic symptoms.
The important point is that incidental does not mean clinically irrelevant.
Learning Objectives
By the end of this article, readers should be able to:
- Recognize the important CT findings of a complex pancreatic cystic lesion.
- Understand why an enhancing mural solid component changes the diagnostic risk assessment.
- Evaluate pancreatic duct communication when considering IPMN.
- Distinguish pancreatic dermoid cyst from important cystic pancreatic neoplasms.
- Understand the complementary roles of CT, MRI/MRCP, EUS, and PET-CT.
- Identify how AI could support pancreatic cystic lesion assessment while preserving radiologist oversight.
Anatomy Review: Why the Pancreatic Tail Matters
The pancreas extends from the head through the neck and body to the tail. The pancreatic tail lies toward the splenic hilum and has close anatomical relationships with the spleen, stomach, left kidney, and regional vessels.
For a cystic lesion in the pancreatic tail, the radiologist should therefore determine not only whether the lesion is intrapancreatic but also how it relates to:
- the pancreatic parenchyma,
- the main pancreatic duct,
- the splenic vessels,
- the spleen,
- the stomach,
- the left kidney,
- regional lymph nodes.
Coronal and sagittal multiplanar reconstructions are particularly useful because they clarify the true longitudinal axis of a lesion and its relationship to adjacent structures.
A cystic mass that appears merely “large” on an axial image may become anatomically much more understandable on multiplanar imaging.
Case Presentation
Patient Profile
A man in his 50s presented with exertional dyspnea and palpitations.
Clinical History
The symptoms had developed after a previous COVID-19 infection.
Relevant Medical History
The case described type 2 diabetes mellitus, hypertension, dyslipidemia, and a relatively high BMI.
Laboratory Findings
- Hemoglobin: normal
- MCV: 70 fL
- D-dimer: 0.9 μg FEU/mL
- CA 19-9: 90.0 kU/L
- CEA: normal
- AFP: normal
- CA 15-3: normal
Initial Imaging
CT pulmonary angiography was performed to evaluate suspected pulmonary embolism.
Pulmonary embolism was not identified.
An incidental cystic lesion was detected in the pancreatic tail.
Dedicated Pancreatic CT
The lesion measured approximately:
4.4 × 3.8 × 5.0 cm
It was described as a lobulated complex cystic mass with an enhancing mural solid component.
Final Diagnosis
After surgical resection, the final pathological diagnosis was:
Pancreatic dermoid cyst.
Imaging Features
Axial CT
Figure 1. Axial CT demonstrating a lobulated cystic lesion in the pancreatic tail.
The lesion is relatively well-defined and lobulated, with predominantly low attenuation compatible with a cystic component. Its morphology is more complex than that of a simple unilocular cyst.
Clinical Significance:
A cystic lesion of approximately 5 cm requires structured morphological assessment rather than being dismissed as an incidental simple cyst.
ALT Text:
Axial CT showing a well-defined lobulated complex cystic mass in the pancreatic tail.
Contrast-Enhanced Axial CT
Figure 2. Contrast-enhanced axial CT demonstrating an enhancing mural solid component.
An enhancing solid component is present along the anterior wall of the cystic lesion. The distinction between simple internal debris and true enhancing tissue is critical.
Clinical Significance:
Enhancement indicates vascularized tissue rather than simple fluid or nonvascular debris. In a pancreatic cystic lesion, an enhancing mural nodule or solid component substantially changes the level of concern.
The correct report should therefore avoid the nonspecific phrase “5-cm pancreatic cyst” and instead communicate the morphology:
“A 5-cm complex cystic pancreatic lesion with an enhancing mural solid component.”
That description directly informs clinical decision-making.
ALT Text:
Contrast-enhanced axial CT showing an enhancing mural solid component within a complex cystic pancreatic tail lesion.
Coronal CT
Figure 3. Coronal CT demonstrating the pancreatic tail lesion and its anatomical relationships.
Coronal reconstruction provides a clearer view of the lesion's longitudinal dimension, lobulated configuration, pancreatic relationship, and surrounding anatomy.
Clinical Significance:
Multiplanar reconstruction helps determine whether a lesion truly arises from the pancreas and clarifies its relationship to adjacent structures, including the spleen, stomach, kidney, and regional vessels.
ALT Text:
Coronal CT demonstrating a lobulated cystic lesion arising from the pancreatic tail.
What Should a Radiologist Look for in a Pancreatic Cystic Mass?
| Imaging Feature | Why It Matters |
|---|---|
| Lesion size | Larger lesions generally require more careful risk assessment |
| Growth rate | Rapid interval growth can increase concern |
| Wall thickness | Thick or irregular walls may be concerning |
| Mural nodule | Enhancement is particularly important |
| Solid component | May indicate neoplastic tissue |
| Septation | Helps characterize lesion complexity |
| Calcification | Pattern and location matter |
| Fat | May provide a clue to dermoid composition |
| Main pancreatic duct | Dilatation may increase concern |
| Duct communication | Important for IPMN assessment |
| Lymph nodes | May support neoplastic disease |
| Vascular invasion | May suggest aggressive disease |
| Distant disease | Changes staging and management |
In this case, the most influential findings were the approximately 5-cm size and enhancing mural solid component, together with elevated CA 19-9.
Why the Enhancing Solid Component Matters
One of the most important radiological distinctions is the difference between:
debris and vascularized tissue.
Proteinaceous material, hemorrhage, or other intracystic contents may appear relatively complex on CT or MRI. However, these materials do not demonstrate true enhancement in the same manner as vascularized tissue.
A mural nodule or solid component should therefore be assessed by comparing precontrast and postcontrast images whenever available.
The question is not simply:
“Is there something inside the cyst?”
The better question is:
“Is there enhancing tissue within or along the cyst wall?”
That distinction can change the clinical pathway.
The Main Pancreatic Duct: A Critical Anatomical Question
The relationship between the cystic lesion and the pancreatic duct is one of the most useful pieces of information in the differential diagnosis of pancreatic cysts.
Branch-duct IPMN arises from the pancreatic ductal system. Demonstrating communication between the lesion and a pancreatic duct therefore strongly influences the diagnostic interpretation.
In this case, no clear communication between the lesion and the main pancreatic duct was identified.
This finding did not prove a dermoid cyst, but it reduced support for an IPMN diagnosis.
This is an important example of how imaging diagnosis works: a negative finding may not establish the final diagnosis, but it can meaningfully change the probability of competing diagnoses.
Pathophysiology of Pancreatic Dermoid Cyst
Pancreatic dermoid cyst is an exceptionally rare benign cystic lesion.
Dermoid cysts are composed of mature tissues derived from germ-cell-related differentiation and may contain elements such as squamous epithelium and skin appendages.
Because of their tissue composition, dermoid cysts may contain:
- fat,
- fat-fluid levels,
- calcification,
- keratinous material,
- complex internal contents.
These features can provide useful radiological clues.
But there is an important limitation:
Not every pancreatic dermoid cyst contains obvious macroscopic fat or calcification.
The present case is particularly instructive because neither internal or mural calcification nor focal fat deposition was clearly identified.
Therefore:
absence of fat does not exclude a pancreatic dermoid cyst.
Why This Case Is Radiologically Difficult
A classic dermoid cyst containing obvious fat and calcification may suggest the diagnosis relatively early.
This lesion was different.
It had:
- a lobulated configuration,
- predominantly cystic attenuation,
- approximately 5 cm size,
- an enhancing mural solid component,
- elevated CA 19-9,
- no clear pancreatic duct communication,
- no definite focal fat,
- no obvious internal or mural calcification.
The combination naturally raised concern for a cystic neoplasm.
This is precisely where rare-disease reasoning becomes important.
“Atypical for the diagnosis” is not equivalent to “impossible for the diagnosis.”
Differential Diagnosis
| Diagnosis | Key Imaging Finding | Clinical Clue | Differentiating Point |
|---|---|---|---|
| Branch-duct IPMN | Cystic lesion communicating with pancreatic duct | Often incidental | Duct communication is important |
| Cystic pNET | Enhancing solid component | May be clinically silent | Somatostatin receptor imaging may contribute |
| MCN | Complex cystic pancreatic mass | Often requires risk assessment | Morphology and duct relationship help |
| Solid pseudopapillary neoplasm | Solid-cystic architecture | Demographic context may help | Often mixed solid and cystic |
| Serous cystic neoplasm | Microcystic or characteristic morphology | Usually incidental | Typical architecture may be helpful |
| Pancreatic pseudocyst | Fluid collection | History of pancreatitis is important | Clinical history and morphology |
| Pancreatic dermoid cyst | Variable complex cystic morphology | Usually asymptomatic | Fat/calcification may be absent |
The most challenging competing diagnoses in this case were cystic pancreatic neuroendocrine tumor and branch-duct IPMN.
Why Cystic pNET Was Considered
A cystic pancreatic neuroendocrine tumor can contain enhancing solid tissue.
That makes it an important consideration when a cystic pancreatic lesion contains an enhancing component.
Gallium DOTA-TOC PET-CT was performed in this case as part of the differential assessment. No somatostatin receptor avidity was identified in the lesion, reducing the likelihood of a somatostatin-receptor-positive neuroendocrine tumor.
However, PET negativity does not establish a dermoid cyst.
This distinction is critical:
A negative functional imaging study can change probability; it does not necessarily establish histology.
Why Branch-Duct IPMN Was Considered
IPMN is a major differential diagnosis for pancreatic cystic lesions.
The key anatomical question is whether the lesion communicates with the pancreatic ductal system.
In the present case, no clear communication with the main pancreatic duct was demonstrated.
This made IPMN less compelling, although imaging alone did not provide definitive exclusion.
For this reason, duct anatomy should be explicitly addressed in radiology reports rather than being omitted.
MRI and MRCP: What They Could Add
MRI and MRCP play complementary roles in pancreatic cyst evaluation.
MRI can improve characterization of internal cystic contents and soft tissues, while MRCP is particularly useful for demonstrating pancreatic duct anatomy and potential communication between a cystic lesion and the ductal system.
A practical MRI/MRCP assessment may include:
- T1-weighted imaging
- T2-weighted imaging
- fat-suppressed sequences
- diffusion-weighted imaging
- ADC
- dynamic contrast enhancement
- mural nodules
- septations
- pancreatic duct communication
- main pancreatic duct caliber
Fat-sensitive sequences may be particularly useful when a dermoid cyst is suspected.
In this patient, however, preoperative MRI/MRCP was not sufficiently available because the facility did not have MRI capability and outpatient scheduling limitations affected the planned evaluation.
That limitation itself is clinically relevant.
CT Versus MRI/MRCP
| Modality | Major Strength | Important Limitation | Best Clinical Question |
|---|---|---|---|
| CTPA | Detects incidental upper abdominal findings | Not optimized for pancreatic characterization | What unexpected lesion is present? |
| Pancreatic CT | Enhancement, calcification, fat, anatomy | Less soft-tissue contrast than MRI | Is there enhancing tissue or calcification? |
| MRI | Soft-tissue and cyst-content characterization | Availability and examination time | What is the internal composition? |
| MRCP | Duct anatomy | Less direct assessment of some calcifications | Does the lesion communicate with the duct? |
| EUS | High-resolution wall and mural assessment | Invasive procedure | Is there a subtle mural nodule or solid component? |
| PET-CT | Functional receptor/metabolic information depending on tracer | Does not provide histologic confirmation | Does the lesion show relevant functional activity? |
No single modality answers every question.
The practical approach is complementary rather than competitive.
EUS and FNA
Endoscopic ultrasound can provide high-resolution assessment of:
- cyst wall,
- mural nodules,
- septations,
- solid components,
- subtle internal debris.
When clinically appropriate, cyst fluid can be sampled for analysis such as:
- CEA,
- amylase,
- cytology,
- molecular markers.
However, FNA does not necessarily provide a definitive diagnosis in every pancreatic cystic lesion.
Dermoid cyst cytology may overlap with other epithelial or lymphoepithelial lesions, and final diagnosis may depend on examination of the resected specimen.
Imaging Physics: Why Enhancement Changes the Interpretation
CT attenuation reflects the degree to which tissues attenuate X-rays.
Simple fluid usually demonstrates relatively low attenuation. Soft tissue demonstrates higher attenuation, and iodinated contrast increases attenuation within vascularized structures.
The diagnostic question in this case is therefore not simply whether a portion of the lesion appears denser than fluid.
It is whether that component changes attenuation after contrast administration.
A true enhancing mural component indicates vascularized tissue.
That is why comparison of precontrast and postcontrast images can be more informative than a single contrast-enhanced image viewed in isolation.
Multiplanar reconstruction adds another layer of information by reducing uncertainty about the spatial relationship between the cyst, pancreatic parenchyma, duct, and adjacent organs.
Radiologist Interpretation
Findings
Approximately 5-cm lobulated complex cystic mass in the pancreatic tail with an enhancing mural solid component. No definite communication with the main pancreatic duct is identified. No regional lymphadenopathy is described. The lesion does not demonstrate obvious focal fat or internal/mural calcification.
Impression
Complex cystic pancreatic tail lesion with an enhancing mural solid component and elevated CA 19-9. Cystic pancreatic neoplasm, including cystic pNET and IPMN-related pathology, should be considered. Pancreatic dermoid cyst remains a rare differential diagnosis despite the absence of classic macroscopic fat or calcification.
The final diagnosis requires pathological correlation when imaging cannot confidently distinguish the lesion.
Clinical Workflow
A practical diagnostic workflow for an incidental pancreatic cystic lesion can be organized as follows:
Incidental pancreatic lesion à Confirm cystic morphology à Measure lesion size à Assess wall and septations à Look for enhancing mural nodule or solid component à Assess pancreatic duct caliber and communication à Evaluate fat and calcification à Assess lymph nodes, vessels, liver, peritoneum, and adjacent organs à Integrate laboratory and clinical information à MRI/MRCP or EUS when appropriate à Multidisciplinary risk assessment à Surveillance or surgical evaluation according to overall risk
The key principle is that management should be based on the total risk profile rather than one isolated feature.
Why Surgery Was Chosen in This Case
The decision for surgical management was influenced by the combination of:
- approximately 5-cm lesion size,
- complex cystic morphology,
- enhancing mural solid component,
- elevated CA 19-9,
- inability to confidently exclude a malignant or premalignant cystic neoplasm,
- inability to establish a definitive diagnosis of dermoid cyst by imaging alone.
The multidisciplinary team recommended surgical resection.
The patient underwent exploratory laparotomy, distal pancreatectomy, and splenectomy.
The postoperative course was described as favorable, and the patient was discharged on postoperative day 9.
Final pathology demonstrated a pancreatic dermoid cyst.
Pathology: What Establishes the Diagnosis?
The definitive diagnosis of a dermoid cyst rests on pathological examination.
Important histological features include:
- mature squamous epithelium,
- keratinous material,
- sebaceous glands,
- hair follicles and other skin appendages.
The presence of skin appendages is particularly useful in distinguishing a dermoid cyst from other cystic lesions, including lymphoepithelial cysts.
This explains why imaging may remain uncertain when a dermoid cyst lacks the classic combination of fat and calcification.
Treatment and Prognosis
Pancreatic dermoid cysts are generally benign lesions.
Reported treatment strategies include cyst excision, pancreatic resection, laparoscopic approaches, and robotic surgery, depending on lesion location, size, anatomy, and diagnostic uncertainty.
External drainage is generally less attractive because of complications such as pancreatic fistula and recurrence.
For a lesion located in the pancreatic tail, distal pancreatectomy may be considered when surgical resection is appropriate.
The present case illustrates an important management balance.
Not every pancreatic cyst should be removed.
Conversely, a cyst with concerning imaging findings should not automatically be observed as if it were a simple benign cyst.
The clinical decision must balance:
risk of malignancy or significant neoplasia
against
risk and morbidity of intervention.
Artificial Intelligence Perspective
Pancreatic cystic lesions are a potentially useful application for medical imaging AI because diagnostic reasoning requires integration of multiple subtle imaging features rather than recognition of a single abnormality.
A future AI system could potentially assist with:
- automated pancreatic segmentation,
- cyst detection,
- lesion size measurement,
- longitudinal growth assessment,
- wall characterization,
- mural nodule detection,
- enhancement analysis,
- pancreatic duct segmentation,
- duct-lesion communication analysis,
- lymph-node detection,
- liver lesion detection,
- structured differential diagnosis support.
However, these capabilities should be regarded as decision support rather than autonomous diagnosis.
The most valuable AI system would not simply answer:
“What is this lesion?”
It would help answer:
“Which imaging features make this lesion clinically important, and what evidence supports the next diagnostic step?”
AI Workflow
A clinically realistic AI workflow could be:
DICOM CT à Pancreas Detection and Segmentation à Cystic Lesion Detection à 3D Lesion Measurement à Wall / Septation / Mural Nodule Analysis à Pre- and Post-Contrast Comparison à Pancreatic Duct Analysis à Risk Feature Extraction à Structured Radiology Support à Radiologist Review à PACS Report Integration
Figure 5. AI workflow
The radiologist remains responsible for the final interpretation.
Enterprise Healthcare Workflow
At hospital scale, an AI system for pancreatic cyst assessment could operate within an enterprise imaging architecture:
DICOM à PACS/Vendor-Neutral Archive à AI Orchestration Layer à Pancreatic Cyst AI Model à Inference/Structured Findings à PACS Visualization à Radiologist à RIS à EMR à Clinical Decision Support
Figure 6. Enterprise Healthcare Workflow
The purpose is not to add another isolated AI application.
The objective is to make AI-generated information available at the point where radiologists already interpret images and clinicians already make decisions.
PACS/RIS/EMR Integration
A useful enterprise implementation would require interoperability rather than simply deploying an image-analysis algorithm.
Relevant technologies may include:
- DICOM for medical images,
- PACS for image interpretation,
- RIS for radiology workflow,
- EMR for longitudinal clinical context,
- HL7 and FHIR for clinical data exchange,
- AI orchestration for model routing,
- audit logging for traceability.
For pancreatic cyst assessment, longitudinal comparison is especially valuable.
An AI system that measures a lesion consistently across serial examinations may provide greater practical value than an algorithm that only analyzes one examination.
Clinical Decision Support
A useful AI-generated decision-support output might contain:
| AI Output | Clinical Value |
|---|---|
| Lesion size | Establishes baseline |
| Volume | Supports longitudinal assessment |
| Growth rate | Helps surveillance assessment |
| Enhancing component | Highlights risk feature |
| Duct communication | Supports IPMN assessment |
| Duct diameter | Adds risk information |
| Calcification | Characterizes internal composition |
| Fat detection | May suggest dermoid composition |
| Lymph nodes | Screens for additional disease |
| Liver lesions | Supports broader staging assessment |
The radiologist should verify each clinically meaningful finding.
AI should not convert uncertainty into false certainty.
AI Limitations
An AI model could fail when:
- the lesion is unusually rare,
- the morphology is atypical,
- image quality is poor,
- contrast timing is suboptimal,
- the pancreatic tail is partially obscured,
- the lesion resembles another cystic neoplasm,
- training data contain few dermoid cysts,
- the model has limited external validation,
- domain shift occurs between hospitals,
- prior examinations are unavailable.
A particularly important problem in this case would be class imbalance.
Pancreatic dermoid cysts are exceptionally rare. A model trained predominantly on common pancreatic cystic lesions may have little opportunity to learn the visual diversity of dermoid cysts.
Therefore, high performance on common pancreatic cysts would not automatically imply reliable recognition of rare dermoid cysts.
Explainable AI
If AI flags an enhancing mural component, the radiologist should be able to inspect the image region responsible for the alert.
Potential explainability tools include:
- lesion localization,
- segmentation overlays,
- confidence scores,
- heat maps,
- feature attribution,
- structured explanations.
However, visualization of an AI heat map does not prove that the model is correct.
Explainability is not the same as accuracy.
The final judgment must remain grounded in the actual images and clinical context.
AI Failure Analysis
| Failure Mode | Possible Consequence | Radiologist Verification |
|---|---|---|
| False negative | High-risk lesion may be undercalled | Review entire pancreas |
| False positive | Unnecessary alarm | Confirm enhancement |
| Poor segmentation | Incorrect measurement | Inspect lesion boundaries |
| Duct mislocalization | Incorrect IPMN assessment | Trace duct anatomy |
| Domain shift | Reduced model performance | Consider local validation |
| Rare disease bias | Dermoid overlooked | Maintain broad differential |
| Artifact | False mural nodule | Review source images |
| Hallucinated explanation | Misleading report support | Verify every claim |
| Alert fatigue | Important alerts ignored | Prioritize clinically meaningful findings |
Future Precision Medicine
The future of pancreatic cyst imaging may extend beyond morphology.
Potential research directions include:
- radiomics,
- multimodal AI,
- vision-language models,
- foundation models,
- radiogenomics,
- federated learning,
- synthetic data,
- longitudinal disease modeling.
For rare lesions such as pancreatic dermoid cyst, federated learning could eventually become useful because individual hospitals may encounter too few cases to build sufficiently diverse datasets independently.
But these technologies remain different from established clinical practice.
A future model may recognize patterns invisible to conventional reporting, but it must still demonstrate external validation, calibration, clinical utility, and safe integration into clinical workflows.
Ten Expert Insights
Expert Insight 1 — Radiologist Perspective
Do not stop at the word “cyst.” The clinically meaningful diagnosis begins with morphology: size, wall, enhancement, solid tissue, duct relationship, and surrounding anatomy.
Expert Insight 2 — Incidental Finding Perspective
The reason for the examination does not determine the importance of an incidental finding. A lesion discovered during CTPA may require a completely different diagnostic pathway.
Expert Insight 3 — Enhancement Perspective
A suspected mural nodule should be evaluated for genuine contrast enhancement. Debris and vascularized tissue have different clinical implications.
Expert Insight 4 — Pancreatic Duct Perspective
The relationship between the cyst and pancreatic ductal anatomy is one of the most useful discriminators in pancreatic cystic disease.
Expert Insight 5 — Rare Disease Perspective
Atypical imaging does not automatically exclude a rare diagnosis. The absence of macroscopic fat and calcification should not eliminate dermoid cyst from consideration when the overall context remains compatible.
Expert Insight 6 — Multiplanar Perspective
Coronal and sagittal images are not optional decorative reconstructions. They can clarify lesion origin, anatomical relationships, and surgical anatomy.
Expert Insight 7 — Multidisciplinary Perspective
When imaging cannot confidently distinguish benign from potentially malignant disease, the decision should incorporate radiology, gastroenterology, surgery, pathology, and relevant laboratory information.
Expert Insight 8 — AI Deployment Perspective
AI is more likely to provide value when it extracts measurable risk features than when it attempts to replace the final diagnosis.
Expert Insight 9 — Enterprise Perspective
A pancreatic cyst AI model has limited practical value if its output remains outside PACS, RIS, and EMR workflows.
Expert Insight 10 — Future Technology Perspective
Rare diseases expose a major weakness of medical AI: a model can perform well on common conditions while remaining unreliable for uncommon pathology.
Clinical Pearls
- An incidental pancreatic cyst should not automatically be considered benign.
- Lesion size should be interpreted together with morphology.
- Enhancing mural tissue is more concerning than simple internal debris.
- Precontrast and postcontrast images should be compared when enhancement is suspected.
- Main pancreatic duct communication is important when considering IPMN.
- MRI/MRCP can provide complementary information to CT.
- EUS can improve evaluation of subtle mural and internal components.
- PET findings can modify diagnostic probability but do not replace pathology.
- Pancreatic dermoid cyst may lack obvious macroscopic fat or calcification.
- CA 19-9 elevation alone does not establish pancreatic malignancy.
- A negative imaging feature may reduce the probability of one diagnosis without proving another.
- Rare benign lesions can mimic malignant or premalignant pancreatic cystic neoplasms.
- Surgery should not be recommended for every pancreatic cyst.
- High-risk morphology requires a balanced multidisciplinary assessment.
- AI should support, not replace, radiologist interpretation.
Common Diagnostic Pitfalls
Pitfall 1 — Calling Every Low-Attenuation Pancreatic Lesion a Simple Cyst
Complex morphology must be evaluated before assigning a benign label.
Pitfall 2 — Ignoring Enhancement
An enhancing mural component can be the most important feature in the entire examination.
Pitfall 3 — Measuring Only the Largest Diameter
Morphology and interval growth may be more informative than a single measurement.
Pitfall 4 — Forgetting the Pancreatic Duct
Failure to evaluate duct communication can weaken the differential diagnosis.
Pitfall 5 — Assuming No Fat Means No Dermoid
The present case demonstrates why that reasoning can fail.
Pitfall 6 — Treating CA 19-9 as a Diagnostic Test for Cancer
An elevated CA 19-9 should be interpreted within the complete clinical and imaging context.
Pitfall 7 — Treating PET Negativity as Histological Diagnosis
Functional imaging modifies probability but does not substitute for pathology.
Pitfall 8 — Overreliance on AI
An AI system may be least reliable precisely when the lesion is rare or atypical.
Pitfall 9 — Ignoring Multiplanar Images
Coronal and sagittal reconstructions may clarify lesion origin and relationships.
Pitfall 10 — Equating “Incidental” With “Unimportant”
Incidental findings can become clinically significant when morphological risk features are present.
Frequently Asked Questions
What is a pancreatic dermoid cyst?
A pancreatic dermoid cyst is a very rare benign cystic lesion containing mature tissue elements such as squamous epithelium and skin appendages. Because it can have variable imaging characteristics, preoperative diagnosis may be difficult.
What is the key CT finding in this case?
The most important CT finding was an approximately 5-cm lobulated complex cystic lesion in the pancreatic tail with an enhancing mural solid component.
Does an enhancing mural component always mean cancer?
No. Enhancement increases concern for neoplastic tissue but is not synonymous with malignancy. This case demonstrates that a benign pancreatic dermoid cyst can mimic a more concerning cystic neoplasm.
Can pancreatic dermoid cyst contain fat?
Yes. Fat can be an important clue because dermoid cysts may contain mature adipose tissue. However, the absence of obvious fat does not exclude the diagnosis.
Can a pancreatic dermoid cyst contain calcification?
Calcification may occur, but it is not mandatory. In this case, internal or mural calcification was not identified.
Why is pancreatic duct communication important?
Communication with the pancreatic duct can support the diagnosis of IPMN. Lack of demonstrated communication can make IPMN less likely but does not by itself establish another diagnosis.
What is the role of MRI/MRCP?
MRI provides improved soft-tissue and cyst-content characterization, while MRCP is particularly useful for evaluating the pancreatic duct and possible communication with the cystic lesion.
What is the role of EUS?
EUS provides high-resolution evaluation of the cyst wall, mural nodules, septations, solid components, and internal debris. FNA may provide additional cyst-fluid information when clinically appropriate.
Does elevated CA 19-9 mean pancreatic cancer?
No. CA 19-9 elevation should not be interpreted in isolation. In this case, the elevated CA 19-9 added concern because it occurred together with an enhancing solid component and a relatively large complex cystic lesion.
Can AI diagnose pancreatic dermoid cyst?
AI may eventually assist with lesion detection, segmentation, measurement, enhancement analysis, duct assessment, and differential support. However, rare lesions such as pancreatic dermoid cyst remain challenging, and AI should not be treated as an autonomous diagnostic authority.
AEO: Direct Clinical Answers
What is a pancreatic dermoid cyst?
A pancreatic dermoid cyst is a rare benign cystic lesion containing mature tissue elements, including squamous epithelium and skin appendages. Imaging may show complex cystic morphology, fat, or calcification, but classic fat or calcification can be absent.
What is the key imaging finding?
In this case, the key imaging finding was a roughly 5-cm lobulated complex cystic mass in the pancreatic tail containing an enhancing mural solid component. That finding increased concern for cystic pancreatic neoplasia despite the eventual benign pathological diagnosis.
When is MRI or MRCP useful?
MRI/MRCP is useful when CT does not fully characterize a pancreatic cystic lesion, particularly when assessment of cyst contents, soft-tissue components, pancreatic duct anatomy, or communication between a cyst and the ductal system is important.
Quiz
Question 1
A 5-cm pancreatic cystic lesion contains a suspected mural nodule. Which finding most strongly determines whether the nodule represents viable tissue?
① Its location in the pancreatic tail
② Its relationship to the stomach
③ Demonstration of true contrast enhancement
④ The patient's absence of abdominal pain
⑤ The patient's history of hypertension
Correct Answer: ③
Explanation:
True contrast enhancement supports the presence of vascularized tissue and is more clinically concerning than simple debris. Comparison between precontrast and postcontrast images is therefore essential.
Question 2
Which imaging feature is particularly important when differentiating branch-duct IPMN from other pancreatic cystic lesions?
① Liver size
② Gallbladder position
③ Pancreatic duct communication
④ Splenic volume
⑤ Gastric peristalsis
Correct Answer: ③
Explanation:
IPMN arises from the pancreatic ductal system. Demonstrating communication between the cystic lesion and the pancreatic duct can therefore be an important diagnostic clue.
Question 3
Which statement best describes the significance of negative Gallium DOTA-TOC PET-CT in this case?
① It proves pancreatic dermoid cyst
② It proves pancreatic adenocarcinoma
③ It excludes all pancreatic neoplasms
④ It reduces the likelihood of a somatostatin-receptor-positive pNET
⑤ It establishes a benign cyst without pathology
Correct Answer: ④
Explanation:
The absence of somatostatin receptor avidity reduced the likelihood of a receptor-positive pancreatic neuroendocrine tumor, but it did not establish the final diagnosis.
Question 4
Which statement is most appropriate regarding the absence of fat and calcification in a suspected pancreatic dermoid cyst?
① Dermoid cyst is completely excluded
② The lesion must be an IPMN
③ The lesion must be a pseudocyst
④ The absence of these findings does not completely exclude dermoid cyst
⑤ Pathology is unnecessary
Correct Answer: ④
Explanation:
Dermoid cysts may contain fat or calcification, but these findings are not present in every case. The present case demonstrates that an atypical imaging pattern can still represent a pancreatic dermoid cyst.
Question 5
Which combination most strongly contributed to the decision for surgical evaluation in this case?
① No symptoms and normal CEA
② Small lesion and normal AFP
③ Approximately 5-cm size, enhancing mural solid component, and elevated CA 19-9
④ Previous COVID-19 infection alone
⑤ Normal hemoglobin and normal CEA
Correct Answer: ③
Explanation:
The clinical decision was driven by the combination of lesion size, concerning morphology, and elevated CA 19-9. None of these findings alone established malignancy, but together they made it difficult to safely exclude a clinically significant cystic neoplasm.
Conclusion
Pancreatic dermoid cyst is an exceptionally rare benign lesion, but this case's most important lesson is not its rarity.
The more important lesson is how a radiologist should respond when imaging findings are concerning but not diagnostic.
A pancreatic tail lesion measuring approximately 5 cm, showing complex cystic morphology and an enhancing mural solid component, appropriately demands further evaluation. Elevated CA 19-9 adds clinical concern but does not establish malignancy. Lack of clear pancreatic duct communication makes IPMN less compelling but does not provide a definitive alternative diagnosis. Negative functional imaging may reduce the probability of cystic pNET without replacing histological confirmation.
The final diagnosis was pancreatic dermoid cyst after surgical resection.
The case therefore reinforces a central principle of diagnostic imaging:
Atypical does not mean impossible, and suspicious does not always mean malignant.
For pancreatic cystic lesions, the radiologist's task is not to force an immediate label. It is to characterize morphology accurately, identify risk features, evaluate ductal anatomy, integrate clinical information, recommend appropriate complementary imaging when necessary, and communicate the degree of diagnostic uncertainty clearly.
In the era of medical AI, this principle becomes even more important.
The most useful AI system will not simply produce a diagnostic label. It will help the radiologist identify the features that matter—enhancing tissue, duct communication, growth, internal composition, and anatomical relationships—while making uncertainty visible.
Ultimately, the quality of pancreatic cyst diagnosis depends not on one image, one biomarker, or one algorithm, but on the integration of morphology, anatomy, clinical context, pathology, and disciplined clinical reasoning.
Key Takeaways
- Incidental pancreatic cystic lesions require structured risk assessment.
- Approximately 5-cm size and complex morphology deserve careful evaluation.
- An enhancing mural solid component is a major imaging risk feature.
- Pancreatic duct communication is important when considering IPMN.
- MRI/MRCP and EUS provide complementary information.
- CA 19-9 elevation increases clinical concern but is not diagnostic of cancer.
- Gallium DOTA-TOC PET-CT can help evaluate suspected pNET but cannot replace pathology.
- Pancreatic dermoid cyst may lack classic fat or calcification.
- Rare benign lesions can mimic malignant or premalignant pancreatic cystic neoplasms.
- AI can assist detection, segmentation, measurement, and risk-feature extraction, but radiologist oversight remains essential.
Continue Learning
- CT Imaging of Pancreatic Cystic Neoplasms
- Imaging Differentiation of Pancreatic IPMN and MCN
- CT Diagnosis of Pancreatic Cancer
- MRI and MRCP of Pancreatic Disease
- Clinical Significance of Elevated CA 19-9
- Imaging of Pancreatic Neuroendocrine Tumors
- Follow-up of Incidentally Detected Pancreatic Cysts
- EUS Evaluation of Pancreatic Cystic Lesions
- Artificial Intelligence in Pancreatic Imaging
- Enterprise AI Workflow for Abdominal Imaging
References
- J. Lane, A. Vance, D. Finelli, G. Williams, and P. Ravichandran, “Dermoid cyst of the pancreas: A case report with literature review,” Journal of Radiology Case Reports, vol. 6, no. 12, pp. 17–25, 2012, doi: 10.3941/jrcr.v6i12.1152.
- A. Albayrak, U. Yildirim, M. Aydin, et al., “Dermoid cyst of the pancreas: A report of an unusual case and a review of the literature,” Case Reports in Pathology, 2013, Art. no. 375193, doi: 10.1155/2013/375193.
- G. H. Elta, B. K. Enestvedt, B. G. Sauer, and A. M. Lennon, “ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts,” American Journal of Gastroenterology, vol. 113, no. 4, pp. 464–479, 2018, doi: 10.1038/ajg.2018.14.
- E. S. Lee, J. H. Kim, M. H. Yu, et al., “Diagnosis and Surveillance of Incidental Pancreatic Cystic Lesions: 2017 Consensus Recommendations of the Korean Society of Abdominal Radiology,” Korean Journal of Radiology, vol. 20, no. 4, pp. 542–557, 2019, doi: 10.3348/kjr.2018.0640.
- European Study Group on Cystic Tumours of the Pancreas, “European evidence-based guidelines on pancreatic cystic neoplasms,” Gut, vol. 67, no. 5, pp. 789–804, 2018, doi: 10.1136/gutjnl-2018-316027.
- S. S. Vege, B. Ziring, R. Jain, and P. Moayyedi, “American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts,” Gastroenterology, vol. 148, no. 4, pp. 819–822, 2015, doi: 10.1053/j.gastro.2015.01.015.
- M. Tanaka, C. Fernández-del Castillo, T. Kamisawa, et al., “Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas,” Pancreatology, vol. 17, no. 5, pp. 738–753, 2017, doi: 10.1016/j.pan.2017.07.007.
- J. S. Kang, T. Park, Y. Han, et al., “Clinical validation of the 2017 international consensus guidelines on intraductal papillary mucinous neoplasm of the pancreas,” Annals of Surgical Treatment and Research, vol. 97, no. 2, pp. 58–64, 2019, doi: 10.4174/astr.2019.97.2.58.
- A. Udare, M. Agarwal, M. Alabousi, et al., “Diagnostic Accuracy of MRI for Differentiation of Benign and Malignant Pancreatic Cystic Lesions Compared to CT and Endoscopic Ultrasound: Systematic Review and Meta-analysis,” Journal of Magnetic Resonance Imaging, vol. 54, no. 4, pp. 1126–1137, 2021, doi: 10.1002/jmri.27606.
- P. Boraschi, R. Cervelli, and F. Donati, “Common cystic pancreatic neoplasms: A comprehensive magnetic resonance imaging-based review of typical and atypical imaging features,” World Journal of Radiology, vol. 18, no. 7, 2026, doi: 10.4329/wjr.120526.
Medical Disclaimer: This article is provided for medical education and informational purposes and is not a substitute for professional diagnosis or treatment. Individual patients should be evaluated by qualified healthcare professionals.
Comments
Post a Comment